IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis

Cellular and Molecular Immunology

Volumn 12, Issue 3, 2015, Pages 366-372

  Li, Qingshan ^a,b   Xu, Xin ^a   Zhong, Weijie ^a   Du, Qinghua ^a   Yu, Bizhen ^a   Xiong, Huabao ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

interleukin 17; irradiation; lymphoma; p53 protein; regulatory T cells

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; PROTEIN P53; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRRADIATION; KARPAS1106 CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RADIATION DOSE; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL SURVIVAL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IONIZING RADIATION; LYMPHOMA, B-CELL; METABOLISM; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LYMPHOMA, B-CELL; RADIATION TOLERANCE; RADIATION, IONIZING; T-LYMPHOCYTES, REGULATORY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928884040     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.122     Document Type: Article

References (30)

1. Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet 2013; 206: 257-265.
2. Rivera-Rodriguez N, Cabanillas F. Recent advances in the management of mantle cell lymphoma. Curr Opin Oncol 2013; 25: 716-721.
3. Domm JA, Thompson M, Kuttesch JF, Acra S, Frangoul H. Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gamma delta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 2005; 27: 607-610.
4. Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T et al. High-dose therapy followed by stem cell transplantation in Hodgkin lymphoma: past and future. Expert Rev Hematol 2013; 6: 451-464.
5. Nowarski RW. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood 2012; 120: 366-375.
6. Sghaier H, Ghedira K, Benkahla A, Barkallah I. Basal DNA repair machinery is subject to positive selection in ionizing-radiationresistant bacteria. BMC Genomics 2008; 9: 297.
7. Kim D, Chung K, Chung W, Bae S, Shin D, Hong S et al. Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. Radiat Oncol 2014; 9: 109.
8. Broustas CG, Lieberman HB. RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels. Prostate 2014; 74: 1359-13570.
9. Best G, Thompson P, Tam CS. Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 2105-2115.
10. de Viron E, Michaux L, Put N, Bontemps F, van den Neste E. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 1445-1451.
11. Li L, Boussiotis VA. The role of IL-17-producing Foxp31CD41 T cells in inflammatory bowel disease and colon cancer. Clin Immunol 2013; 148: 246-253.
12. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 2009; 158: 199-204.
13. Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72: 3987-3996.
14. Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S, Zdravkovic N et al. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2010; 57: 135-144.
15. Sun AM, Li CG, Han YQ, Liu QL, Xia Q, Yuan YW. X-ray irradiation promotes apoptosis of hippocampal neurons through up-regulation of Cdk5 and p25. Cancer Cell Int 2013; 13: 47.
16. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013; 171: 36-45.
17. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD et al. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010; 76: 1214-1224.
18. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-1835.
19. Kim SH, Dass CR. p53-Targeted cancer pharmacotherapy: move towards small molecule compounds. J Pharm Pharmacol 2011; 63: 603-610.
20. Solanki AA, LeMieux MH, Chiu BC, Mahmood U, Hasan Y, Koshy M. Long-Term outcomes in patients with early stage nodular lymphocytepredominant hodgkin lymphoma treated with radiotherapy. PLoS ONE 2013; 8: e75336.
21. Cheng JC, Bai A, Beckham TH, Marrison ST, Yount CL, Young K et al. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest 2013; 123: 4344-4358.
22. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-4665.
23. Wedlake LJ, Khan K, Ahmedi B, Thomas K, Abraham D, Andreyev N. Letter in response to article: a pilot study examining circulating interleukin-6 and transforming growth factor-beta levels during pelvic radiation therapy. Am J Clin Oncol 2013; 36: 102-103.
24. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004; 111: 653-661.
25. Chen MF, Hsieh CC, Chen WC, Lai CH. Role of interleukin-6 in the radiation response of liver tumors. Int J Radiat Oncol Biol Phys 2012; 84: e621-e630.
26. Gougelet A, Mansuy A, Blay JY, Alberti L, Vermot-Desroches C. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS ONE 2009; 4: e8026.
27. Wang BQ, Zhang CM, Gao W, Wang XF, Zhang HL, Yang PC. Cancerderived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol 2011; 137: 1525-1533.
28. Hemdan NY. Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol Lett 2013; 149: 123-133.
29. Qu Y, Zhang B, Liu S, Zhang A, Wu T, Zhao Y. 2-Gy whole-body irradiation significantly alters the balance of CD41CD252 T effector cells and CD41CD251Foxp31 T regulatory cells in mice. Cell Mol Immunol 2010; 7: 419-427.
30. Ganesan AP, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013; 191: 2009-2017.